Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: Differences between second messenger and reporter gene responses

Molecular Pharmacology

Volumn 64, Issue 3, 2003, Pages 679-688

  Baker, Jillian G ^a   Hall, Ian P ^a   Hill, Stephen J ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ADRENALIN; BETA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; GREEN FLUORESCENT PROTEIN; ISOPRENALINE; PARTIAL AGONIST; PROPRANOLOL; SALBUTAMOL; TERBUTALINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMICAL INTERACTION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; DRUG RECEPTOR BINDING; GENETIC TRANSCRIPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPORTER GENE; SECOND MESSENGER;

ADRENERGIC AGONISTS; ADRENERGIC ANTAGONISTS; ANIMALS; CHO CELLS; CRICETINAE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, REPORTER; HUMANS; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, ADRENERGIC, BETA-2; SECOND MESSENGER SYSTEMS;

EID: 0042856422     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.3.679     Document Type: Article

References (29)

1. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48-58.
2. Baker JG, Hall IP, and Hill SJ (2002a) Pharmacological characterization of CGP 12177 at the human β2-adrenoceptor. Br J Pharmacol 137:400-408.
3. 2-adrenoceptor. Br J Pharmacol 136:5P.
4. Baker JG, Hall IP, and Hill SJ (2003) Time course of agonist-stimulated CRE-mediated reporter gene transcription in CHO cells Br J Pharmacol 138: 127P.
5. Black JW, Duncan WA, Durant CJ, Ganellin CR, and Parsons ME (1972) Definition and antagonism of histamine H2-receptors. Nature (Lond) 236:385-390.
6. Black JW, Duncan WAM, and Shanks RG (1965) Comparison of some properties of pronethalol and propranolol. Br J Pharmacol 25:577-591.
7. Clark RB, Knoll BJ, and Barber R (1999) Partial agonists and G-protein coupled receptor desensitization Trends Pharmacol Sci 20:279-286.
8. Cullen BR and Malim MH (1992) Secreted placental alkaline phosphatase as a eukaryotic reporter gene. Methods Enzymol 216:362-368.
9. Donaldson J, Brown AM, and Hill SJ (1988) Influence of roliprarn on the cyclic-3′, 5′-adenosine monophosphate response to histamine and adenosine in slices of guinea-pig cerebral cortex. Biochem Pharmacol 37:715-723.
10. 2-adrenergic receptor. J Biol Chem 23:13796-13803.
11. Hill SJ, Baker JG, and Rees S (2001) Reporter gene systems for the study of G-protein-coupled receptors. Curr Opin Pharmacol 1:526-532.
12. 2-adrenoceptors. Br J Pharmacol 131: 124-130.
13. 2-adrenoceptor. Br J Pharmacol 123:701-711.
14. January B, Seibold A, Whaley B, Hipkin RW, Lin D, Schonbrunn A, Barber R, and Clark RB (1997) β2-Adrenergic receptor desensitization, internalization and phosphorylation in response to full and partial agonists. J Biol Chem 272: 23871-23879.
15. Kenakin T and Boselli C (1989) Pharmacologic discrimination between receptor heterogeneity and allosteric interaction: resultant analysis of gallamine and pirenzepine antagonism of muscarinic responses in rat trachea. J Pharmacol Exp Ther 250:944-952.
16. Kenakin T, Morgan P, and Lutz M (1995) On the importance of the "antagonist assumption" to how receptors express themselves. Biochem Pharmacol 50:17-26.
17. Kenakin T and Onaran O (2002) The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 23:275-280.
18. Kobilka B (1992) Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci 15:87-114.
19. Kohout TA and Lefkowitz RJ (2003) Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 63:9-18.
20. 1-adrenergic receptors. J Pharmacol Exp Ther 294:923-932.
21. Krupnick JG and Benovic JL (1998) The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 38:289-319.
22. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
23. MacEwan DJ, Kim GD, and Milligan G (1995) Analysis of the role of receptor number in defining the intrinsic activity and potency of partial agonists in neuroblastoma x glioma hybrid NG108-15 cells transfected to express differing levels of the human β2-adrenoceptor. Mol Pharmacol 48:316-325.
24. 2-adrenoceptor. Br J Pharmacol 125:717-726.
25. Motulsky HJ and Mahan LC (1984) The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25:1-9.
26. Rees S, Brown S, and Stables J (1999) Reporter gene systems for the study of G protein-coupled receptor signal transduction in mammalian cells, in Signal Transduction: A Practical Approach, 2nd ed, (Milligan G ed) p. 171-222, Oxford University Press. Oxford.
27. 2-adrenergic receptor by the GRK pathway. Mol Pharmacol 58:1162-1173.
28. Tsao P, Cao T, and von Zastrow M (2001) Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol Sci 22:91-96.
29. Yuan N, Friedman J, Whaley BS, and Clark RB (1994) cAMP-dependent protein kinase and protein kinase C consensus site mutations of the β-adrenergic receptor. Effect on desensitizaton and stimulation of adenylyl cyclase. J Biol Chem 269:23032-23038.